Based on the observations of frequent upregulation of HER2 in HR+/HER2- BC, short-term NET while patients are awaiting surgery may therefore identify HR+/HER2- tumors that engage HER2-signaling to overcome ET. This evidence concerns the gene ERBB2 and breast cancer.